COO

Business Profile & Competitive Position

The Cooper Companies, Inc. operates within the Healthcare sector and the Medical - Instruments & Supplies industry. Its business is split into two segments. CooperVision develops, manufactures, and markets daily, two-week, and monthly contact lenses as well as specialty eye-care products, including silicone hydrogel lenses, MiSight 1 day for myopia management, orthokeratology lenses, and scleral lenses. CooperSurgical supplies more than 600 products and services focused on fertility and women’s health, spanning gynecology, obstetrics, contraception, labor and delivery, cord blood/tissue storage, IVF support, donor gametes, cryopreservation, and genomic services.

The company’s products are sold in over 130 countries and reach more than 50 million lives annually. Approximately 500 employees work in research and development across both segments. Its MiSight 1 day lens is the only contact lens approved by the FDA, China’s NMPA, and Japan’s MHLW to slow the progression of, and correct, myopia in age-appropriate children.

What the profitability numbers say about competitive strength is more measured. The net margin is 5.6% and return on equity is 2.8%. Those figures do not point to a wide-moat, hyper-efficient franchise; they suggest capital intensity, ongoing investment, or pricing pressure in parts of the portfolio. The P/E of 59.3 implies the market is pricing growth and regulatory differentiation rather than current capital efficiency alone. The regulatory approvals for MiSight add a real, if narrow, asset, but the overall margin profile supports treating the moat as tentative rather than dominant.

Financial Posture

The Cooper Companies carries a market capitalization of $13.6 billion, trades at a trailing price-to-earnings ratio of 59.3, and has a beta of 0.82. The low beta fits the Healthcare sector’s historically defensive demand profile, especially for consumable medical products such as contact lenses and surgical supplies.

Profitability metrics, however, create a sharp contrast with valuation. The net margin is 5.6% and ROE is 2.8%. A P/E near 60x against sub-3% ROE and a mid-single-digit net margin is an unusual pairing; it normally reflects investor confidence in margin recovery, revenue acceleration, or durable segment-level growth not yet visible in trailing returns. The snapshot shows the stock at $69.925, with the 50-day exponential moving average at $72.17 and RSI at 35.0. That RSI reading is approaching the traditional oversold threshold, while the price sits below its 50-day EMA, a combination technicians often watch for momentum shift. No debt figure is included in the provided snapshot, so leverage cannot be judged from this data alone.

Strategic Priorities & Outlook

The company’s most recent 10-K filing outlines a clear operational focus for both segments. For CooperVision, management emphasizes:

• Greater worldwide market penetration of recently introduced products and expansion in both existing and emerging markets.
• Increasing investment in distribution and packaging capabilities to support growth and maintain service levels.
• Investing to develop the myopia-management market through education of eye-care practitioners, patients, and families.

For CooperSurgical, the filing points to continued business investment, including through strategic transactions, to expand the integrated solutions model within fertility and women’s health.

Those priorities carry a unifying theme: build share in contact lenses and myopia management at CooperVision while assembling a broader fertility and women’s-health platform at CooperSurgical. Execution risk sits on both fronts, CooperVision in international distribution scale and market education, and CooperSurgical in integration of acquired assets and services.

Macro & Geopolitical Exposure

As a Medical - Instruments & Supplies company with global distribution, Cooper Companies is exposed to several broad macro and geopolitical forces. Regulatory risk is significant: contact lenses and fertility devices require clearances from the FDA, China’s NMPA, Japan’s MHLW, and other national regulators, and any changes in approval timelines or labeling requirements can affect launches.

Currency exposure is also material. With products sold in over 130 countries, revenue is sensitive to dollar strength against the euro, yen, Chinese yuan, and emerging-market currencies. Trade policy matters as well: tariffs or logistics disruptions on medical-device components, packaging materials, or sterilized supplies can squeeze costs or delay shipments.

On the demand side, contact-lens usage is influenced by near work and myopia trends, while fertility spending can be sensitive to economic cycles, employment, and discretionary household budgets. Reimbursement policy for women’s health and fertility services adds another macro layer that can affect CooperSurgical volumes over time.

Recent Developments

The latest headline flow for the “COO” ticker is somewhat distorted by acronym overlap, with several recent items referring to other companies’ chief operating officers rather than The Cooper Companies itself:

• 2026-08-28 — Unity Software COO Alexander Blum Sells 22,559 Shares for $1 Million (fool.com)
• 2026-08-23 — Rigetti Computing's COO Sells Over 9,000 Company Shares. What Does That Mean for Investors? (fool.com)
• 2026-08-21 — COO vs. MMSI: Which Stock Is the Better Value Option? (zacks.com)
• 2026-08-19 — Target Corp (TGT) (Q2 2026) Earnings Call Highlights: Comparable Sales Surge 3.8% and Full-Year Guidance Raised (gurufocus.com)

Only the Zacks headline directly compares The Cooper Companies (COO) against Merit Medical Systems (MMSI) from a value perspective; the other headlines are unrelated to Cooper’s fundamentals. The absence of company-specific operating news in this window means traders heading into the September report are working mostly from the earnings setup rather than from fresh corporate developments.

Earnings Behavior & Post-Earnings Drift

Cooper Companies has beaten earnings estimates in all 8 of the last 8 reported quarters, with an average earnings surprise of 4.6%. Despite that perfect beat rate, the average 5-day price move after those reports is −0.91%, classified as a “down” post-earnings drift. That tension is worth emphasizing: the company reliably exceeds analyst estimates, yet the market has not consistently rewarded the stock in the days that follow.

The last four reports illustrate the volatility:

• 2026-06-04: actual EPS of $1.21 versus estimate $1.10, a 10.0% surprise. The stock rose 8.58% the next day and 8.85% over the following five sessions.
• 2026-03-05: actual EPS of $1.10 versus estimate $1.03, a 6.8% surprise. The stock fell 4.55% the next day and 10.82% over the next five sessions.
• 2025-12-04: actual EPS of $1.15 versus estimate $1.11, a 3.6% surprise. The stock gained 5.67% the next day and 6.59% over the next five sessions.
• 2025-08-27: actual EPS of $1.10 versus estimate $1.07, a 2.8% surprise. The stock dropped 12.86% the next day and 8.24% over the next five sessions.

The next scheduled report is 2026-09-09 after the close, with consensus EPS at $1.12. With the stock at $69.925 and a 50-day EMA of $72.17, traders will likely be watching whether a ninth consecutive beat can produce follow-through, or whether the recent pattern of post-earnings disappointment reasserts itself.

For readers who want to go deeper, the full institutional verdict — covering analyst consensus trajectory, estimate revisions, and aggregate rating dispersions — is worth reviewing before drawing any conclusions.